Skip to main content
Premium Trial:

Request an Annual Quote

Pareto, DNA2.0 Partner on Synthetic Biology Applications

NEW YORK (GenomeWeb) – Synthetic biology startup Pareto Biotechnologies announced today a technology partnership with DNA2.0 to integrate their technologies to hasten the engineering of proteins in Pareto's pipeline.

Pareto, based in San Francisco, said it will merge its synthetic biology pipeline platform with DNA2.0's ProteinGPS engineering technology to identify and quantify protein genetic mutations for incorporation into iterative rounds of improved synthetic genes. Pareto will also leverage DNA2.0's technologies to "increase the efficacy of its own platform to generate flavors, fragrances, and cosmetics with improved and novel properties," it added in a statement.

Financial and other terms of the deal were not disclosed.

"Our deep understanding of the structures of these classes of enzymes, along with a statistical optimization algorithm from DNA2.0 gets us the best of both worlds: rational design and robust enzyme improvement," Pareto CEO Jamie Bacher said. "Through our relationship with DNA2.0, we'll be able to generate completely novel molecules with applicability to flavors and fragrances, cosmetics, and therapeutics."

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.